Dr. Gibney on the Potential for Fixed-Duration Immunotherapy in Melanoma
Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.
Dr. Gibney on Determining Optimal Treatment Duration With Anti–PD-1 Agents in Melanoma
Geoffrey T. Gibney, MD, discusses efforts made to determine the optimal duration of treatment with anti–PD-1 agents in patients with melanoma.
Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma
Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
2 Commerce Drive Cranbury, NJ 08512